Your browser doesn't support javascript.
loading
Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenance.
Fung, Victor S C; Aldred, Jason; Arroyo, Martha P; Bergquist, Filip; Boon, Agnita J W; Bouchard, Manon; Bray, Sarah; Dhanani, Sara; Facheris, Maurizio F; Fisseha, Nahome; Freire-Alvarez, Eric; Hauser, Robert A; Jeong, Anna; Jia, Jia; Kukreja, Pavnit; Soileau, Michael J; Spiegel, Amy M; Talapala, Saritha; Tarakad, Arjun; Urrea-Mendoza, Enrique; Zamudio, Jorge; Pahwa, Rajesh.
Afiliación
  • Fung VSC; Movement Disorders Unit, Westmead Hospital, Westmead, NSW, Australia.
  • Aldred J; Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
  • Arroyo MP; Inland Northwest Research, Spokane, WA, USA.
  • Bergquist F; Selkirk Neurology, Spokane, WA, USA.
  • Boon AJW; Lakeside Dermatology, Libertyville and Gurnee, IL, USA.
  • Bouchard M; Department of Pharmacology, University of Gothenburg, Gothenburg, Sweden.
  • Bray S; Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Dhanani S; Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
  • Facheris MF; Clinique Neuro-Lévis, Université Laval, Lévis, QC, Canada.
  • Fisseha N; Centre de Recherche St-Louis, Lévis, QC, Canada.
  • Freire-Alvarez E; Movement Disorders Unit, Westmead Hospital, Westmead, NSW, Australia.
  • Hauser RA; Banner Sun Health Research Institute, Sun City, AZ, USA.
  • Jeong A; AbbVie Inc., North Chicago, IL, USA.
  • Jia J; AbbVie GK, Tokyo, Japan.
  • Kukreja P; Neurology Department, University General Hospital of Elche, Elche, Spain.
  • Soileau MJ; Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, FL, USA.
  • Spiegel AM; AbbVie Inc., North Chicago, IL, USA.
  • Talapala S; AbbVie Inc., North Chicago, IL, USA.
  • Tarakad A; AbbVie Inc., North Chicago, IL, USA.
  • Urrea-Mendoza E; Texas Movement Disorder Specialists, Georgetown, TX, USA.
  • Zamudio J; AbbVie Inc., North Chicago, IL, USA.
  • Pahwa R; AbbVie Inc., North Chicago, IL, USA.
Clin Park Relat Disord ; 10: 100239, 2024.
Article en En | MEDLINE | ID: mdl-38419617
ABSTRACT

Background:

As Parkinson's disease (PD) advances, management is challenged by an increasingly variable and inconsistent response to oral dopaminergic therapy, requiring special considerations by the provider. Continuous 24 h/day subcutaneous infusion of foslevodopa/foscarbidopa (LDp/CDp) provides steady dopaminergic stimulation that can reduce symptom fluctuation.

Objective:

Our aim is to review the initiation, optimization, and maintenance of LDp/CDp therapy, identify possible challenges, and share potential mitigations.

Methods:

Review available LDp/CDp clinical trial data for practical considerations regarding the management of patients during LDp/CDp therapy initiation, optimization, and maintenance based on investigator clinical trial experience.

Results:

LDp/CDp initiation, optimization, and maintenance can be done without hospitalization in the clinic setting. Continuous 24 h/day LDp/CDp infusion can offer more precise symptom control than oral medications, showing improvements in motor fluctuations during both daytime and nighttime hours. Challenges include infusion-site adverse events for which early detection and prompt management may be required, as well as systemic adverse events (eg, hallucinations) that may require adjustment of the infusion rate or other interventions. A learning curve should be anticipated with initiation of therapy, and expectation setting with patients and care partners is key to successful initiation and maintenance of therapy.

Conclusion:

Continuous subcutaneous infusion of LDp/CDp represents a promising therapeutic option for individuals with PD. Individualized dose optimization during both daytime and nighttime hours, coupled with patient education, and early recognition of certain adverse events (plus their appropriate management) are required for the success of this minimally invasive and highly efficacious therapy.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Clin Park Relat Disord Año: 2024 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Clin Park Relat Disord Año: 2024 Tipo del documento: Article País de afiliación: Australia